Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The combination of docetaxel and fluorouracil (DF) was compared with epirubicin, cisplatin and fluorouracil in a randomized Phase II trial in the treatment of advanced gastric cancer. The combinations proved equally efficacious but the toxicity profiles favored DF, with less nausea and vomiting. DF appears to be a promising regimen for this disease.

Docetaxel and Continuous-Infusion Fluorouracil vs Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma